Díaz GEJ, Sánchez AR, Santibañez SV, Regules SS

Language: Spanish
References: 18
Page: 361-366
PDF size: 223.94 Kb.

ABSTRACT

Cardiorenal syndrome (CRS) is a multi-organ disease that includes conditions resulting in increased circulating volume due to the interaction between dysfunctions of the heart, kidneys, and metabolic syndrome (MS). Cardiorenal metabolic syndrome is defined as a group of disorders that includes the presence of type 2 diabetes, chronic kidney disease, and heart failure, which are associated with significant morbidity and mortality since patients with heart failure have a four-fold higher prevalence of type 2 diabetes (20%), which in turn doubles the risk of cardiovascular disease (CVD). Similarly, the prevalence of chronic kidney disease increases to 40% in people with type 2 diabetes and 50% in patients with heart failure. Its pathophysiology involves various hemodynamic disorders (changes in systemic and pulmonary vascular resistances, increased central venous pressure, impaired cardiac output, and fluid overload) along with metabolic, neurohormonal, and inflammatory disorders (atherosclerotic degeneration, reactive oxygen species [ROS], nitric oxide production, endothelial dysfunction, and tissue fibrosis) that lead to impaired systemic perfusion and increased cardiovascular risk.

REFERENCES

1. Marassi M, Fadini GP. The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol. 2023; 22 (1): 195. doi: 10.1186/s12933-023-01937-x.

2. Gembillo G, Visconti L, Giusti MA, Siligato R, Gallo A, Santoro D et al. Cardiorenal syndrome: new pathways and novel biomarkers. Biomolecules. 2021; 11 (11): 1581. doi: 10.3390/biom11111581.

3. Raina R, Nair N, Chakraborty R, Nemer L, Dasgupta R, Varian K. An update on the pathophysiology and treatment of cardiorenal syndrome. Cardiol Res. 2020; 11 (2): 76-88. doi: 10.14740/cr955.

4. Mattina A, Argano C, Brunori G, Lupo U, Raspanti M, Lo Monaco M et al. Clinical complexity and diabetes: a multidimensional approach for the management of cardiorenal metabolic syndrome. Nutr Metab Cardiovasc Dis. 2022; 32 (12): 2730-2738. doi: 10.1016/j.numecd.2022.09.008.

5. Méndez Fernández AB, Vergara Arana A, Olivella San Emeterio A, Azancot Rivero MA, Soriano Colome T, Soler Romeo MJ. Cardiorenal syndrome and diabetes: an evil pairing. Front Cardiovasc Med. 2023; 10: 1185707. doi: 10.3389/fcvm.2023.1185707.

6. Poplawski J, Radmilovic A, Montina TD, Metz GAS. Cardiorenal metabolic biomarkers link early life stress to risk of non-communicable diseases and adverse mental health outcomes. Sci Rep. 2020; 10 (1): 13295. doi: 10.1038/s41598-020-69866-3.

7. Akiyama H, Nishimura A, Morita N, Yajima T. Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome. Front Endocrinol (Lausanne). 2023; 14: 1111984. doi: 10.3389/fendo.2023.1111984.

8. Ricciardi CA, Gnudi L. Vascular growth factors as potential new treatment in cardiorenal syndrome in diabetes. Eur J Clin Invest. 2021; 51 (9): e13579. doi: 10.1111/eci.13579.

9. Hoveling LA, Liefbroer AC, Bültmann U, Smidt N. Understanding socioeconomic differences in metabolic syndrome remission among adults: what is the mediating role of health behaviors? Int J Behav Nutr Phys Act. 2021; 18 (1): 147. doi: 10.1186/s12966-021-01217-5.

10. Kosiorek A, Biegus J, Rozentryt P, Hurkacz M, Zymli?ski R. Cardiorenal syndrome: Decongestion in heart failure across wide spectrum of kidney pathophysiology. Adv Clin Exp Med. 2022; 31 (4): 445-455. doi: 10.17219/acem/144327.

11. Morales Villegas EC. El síndrome metabólico cardiovascular renal: una reconstrucción del concepto de síndrome metabólico impulsada por la evidencia terapéutica 2013-2023 [Internet]. Aguascalientes: Centro de Investigación Cardiometabólica de Aguascalientes; 2023. Disponible en: http://academiaelcic.com/el-sindrome-metabolico-cardiovascular-renal/

12. Hinds TD Jr, Stec DE. Bilirubin safeguards cardiorenal and metabolic diseases: a protective role in health. Curr Hypertens Rep. 2019; 21 (11): 87. doi: 10.1007/s11906-019-0994-z.

13. Hou YC, Zheng CM, Yen TH, Lu KC. Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection. Int J Mol Sci. 2020; 21 (21): 7833. doi: 10.3390/ijms21217833.

14. Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab. 2019; 21 (6): 1291-1298. doi: 10.1111/dom.13670.

15. D'Elia JA, Bayliss GP, Weinrauch LA. The diabetic cardiorenal nexus. Int J Mol Sci. 2022; 23 (13): 7351. doi: 10.3390/ijms23137351.

16. Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021; 20 (1): 189. doi: 10.1186/s12933-021-01366-8.

17. Lv R, Xu L, Che L, Liu S, Wang Y, Dong B. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus. Front Endocrinol (Lausanne). 2023; 14: 1125693. doi: 10.3389/fendo.2023.1125693.

18. Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS et al. Salud cardiovascular, renal y metabólica: un consejo presidencial de la Asociación Americana del Corazón. Circulación. 2023; 148 (20): 1606-1635. doi: 10.1161/cir.0000000000001184.